Scinai Immunotherapeutics LtdNASDAQ:SCNINASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4500
- TODAY'S CHANGE (%)-0.0078 (-1.7107%)
- Bid / Lots0.4500/ 39
- Ask / Lots0.4700/ 1
- Open / Previous Close0.4500 / 0.4578
- Day Range
- 52 Week Range
- Volume17,756
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SCNI |
|---|---|---|
| 09:38 ET | 100 | 0.45 |
| 09:39 ET | 5000 | 0.45 |
| 09:45 ET | 9006 | 0.44 |
| 09:52 ET | 200 | 0.44 |
| 11:33 ET | 200 | 0.45 |
| 11:36 ET | 2957 | 0.469899 |
| 11:40 ET | 100 | 0.45 |
Apr 10, 2024
Apr 8, 2024
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services, from 7:00AM ET on Monday Apr 08, 2024 by Dow Jones
7:00AM ET on Monday Apr 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Scinai Immunotherapeutics Ltd | 2.0M | -0.1x | --- |
Panbela Therapeutics Inc | 2.0M | 0.0x | --- |
CTT Pharmaceutical Holdings Inc | 2.1M | -0.4x | --- |
VG Life Sciences Inc | 2.1M | 0.0x | --- |
Qualigen Therapeutics Inc | 1.8M | -0.1x | --- |
Mosaic Immunoengineering Inc | 2.3M | -2.2x | --- |
Company Information
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Contact Information
- Headquarters
- Jerusalem Biopark 2Nd Floor, Hadassah Ein Kerem CampusJERUSALEM, Israel 00000
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Mark Germain
- Chief Executive Officer, Director
- Amir Reichman
- Chief Financial Officer
- Uri Ben-Or
- Chief Operating Officer
- Elad Mark
- Chief Scientific Officer
- Tamar Ben-Yedidia
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.9K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.45 |
EPS | $-4.16 |
Book Value | $-0.71 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
